Show simple item record

dc.contributor.authorAbongomera, C
dc.contributor.authorDiro, E
dc.contributor.authorde Lima Pereira, A
dc.contributor.authorBuyze, J
dc.contributor.authorStille, K
dc.contributor.authorAhmed, F
dc.contributor.authorvan Griensven, J
dc.contributor.authorRitmeijer, K
dc.date.accessioned2018-06-12T14:57:44Z
dc.date.available2018-06-12T14:57:44Z
dc.date.issued2018-05-25
dc.date.submitted2018-06-04
dc.identifier.citationThe initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study. 2018, 12 (5):e0006527 PLoS Negl Trop Disen
dc.identifier.issn1935-2735
dc.identifier.pmid29799869
dc.identifier.doi10.1371/journal.pntd.0006527
dc.identifier.urihttp://hdl.handle.net/10144/619175
dc.description.abstractNorth-west Ethiopia faces the highest burden world-wide of visceral leishmaniasis (VL) and HIV co-infection. VL-HIV co-infected patients have higher (initial) parasitological failure and relapse rates than HIV-negative VL patients. Whereas secondary prophylaxis reduces the relapse rate, parasitological failure rates remain high with the available antileishmanial drugs, especially when administered as monotherapy. We aimed to determine the initial effectiveness (parasitologically-confirmed cure) of a combination of liposomal amphotericin B (AmBisome) and miltefosine for treatment of VL in HIV co-infected patients.
dc.language.isoenen
dc.publisherPublic Library of Scienceen
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseasesen
dc.titleThe initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort studyen
dc.identifier.journalPLoS Neglected Tropical Diseasesen
refterms.dateFOA2019-03-04T14:01:30Z
html.description.abstractNorth-west Ethiopia faces the highest burden world-wide of visceral leishmaniasis (VL) and HIV co-infection. VL-HIV co-infected patients have higher (initial) parasitological failure and relapse rates than HIV-negative VL patients. Whereas secondary prophylaxis reduces the relapse rate, parasitological failure rates remain high with the available antileishmanial drugs, especially when administered as monotherapy. We aimed to determine the initial effectiveness (parasitologically-confirmed cure) of a combination of liposomal amphotericin B (AmBisome) and miltefosine for treatment of VL in HIV co-infected patients.


Files in this item

Thumbnail
Name:
Abongomera C et al - 2018 - The ...
Size:
535.5Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record